ホーム › 非ホジキンリンパ腫 › テネシー › Nashville
Nashville、TNにおける非ホジキンリンパ腫の臨床試験
Nashvilleとその周辺地域（約30マイル以内）の拠点で、非ホジキンリンパ腫に関する21件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
被験者募集中第1/2相
- Tennessee Oncology, Pllc Nashville, Nashville
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
被験者募集中第2相
- Vanderbilt University/Ingram Cancer Center, Nashville
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
被験者募集中第1/2相
- SCRI Oncology Partners ( Site 0100), Nashville
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
被験者募集中第2相
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
被験者募集中第1相
- SCRI Oncology Partners, Nashville
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
被験者募集中第1相
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
被験者募集中第2相
- Research Site, Nashville
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
被験者募集中第2相
- Tennessee Oncology, Nashville
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
被験者募集中第1相
- SCRI Oncology Partners, Nashville
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
被験者募集中第1/2相
- Research Site, Franklin · 17マイル先
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
被験者募集中第1/2相
- Vanderbilt University Medical Center, Nashville
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
被験者募集中第3相
- Sarah Cannon Research Institute SCRI, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
被験者募集中第1/2相
- TriStar BMT, Nashville
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
被験者募集中第3相
- SCRI Oncology Partners, Nashville
DALY II USA/ MB-CART2019.1 for DLBCL
被験者募集中第2相
- SCRI Oncology Partners, Nashville
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- Vanderbilt University, Nashville
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
被験者募集中第4相
- Tennessee Oncology, Nashville
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
被験者募集中第4相
- Tennessee Oncology, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Nashville
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
被験者募集中第1/2相
- SCRI Oncology Partners, Nashville
他の都市における非ホジキンリンパ腫の試験
- New York City, NY31件の研究
- Houston, TX31件の研究
- Boston, MA26件の研究
- Philadelphia, PA20件の研究
- Baldwin Park, CA19件の研究
- Washington, DC18件の研究
- Atlanta, GA18件の研究
- Chicago, IL18件の研究
- Milwaukee, WI18件の研究
- Columbus, OH18件の研究
- Dallas, TX17件の研究
- Seattle, WA16件の研究
Nashvilleにおける他の研究
- 非小細胞肺癌97件の研究
- 乳がん81件の研究
- 転移性癌70件の研究
- 大腸癌69件の研究
- がん（全種類）65件の研究
- 卵巣がん49件の研究
- 前立腺がん43件の研究
- 肺がん40件の研究
- 頭頸部扁平上皮癌39件の研究
- 膵臓がん39件の研究
- 子宮内膜がん38件の研究
- 悪性黒色腫33件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。